Adjuvant Therapy, Liver Cancer, Sarcomatoid Carcinoma
Conditions
Brief summary
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Interventions
PROCEDUREpostoperative adjuvant therapy
Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
Sponsors
West China Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. patients who underwent liver resection 2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Exclusion criteria
1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy; 2. patients diagnosed with other specific types of sarcomas; 3. patients with concurrent other malignancies during the course of PHSC; 4. patients who were lost to follow-up or lacked essential clinical data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | From December 2018 to May 2023 | Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From December 2018 to May 2023 | Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up. |
Countries
China
Contacts
Primary ContactJiwei Huang Professor
Outcome results
None listed